Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Diagnosis and treatment of warfarin resistance].

Tan S, Zhou X, Li Z, Zhang W, Liu Z, Zhou H.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Mar;38(3):313-7. doi: 10.3969/j.issn.1672-7347.2013.03.016. Review. Chinese.

2.

Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.

Hirai K, Hayashi H, Ono Y, Izumiya K, Tanaka M, Suzuki T, Sakamoto T, Itoh K.

Drug Metab Pharmacokinet. 2013;28(2):132-7. Epub 2012 Aug 14.

3.

Comparative genetics of warfarin resistance.

Oldenburg J, Müller CR, Rost S, Watzka M, Bevans CG.

Hamostaseologie. 2014;34(2):143-59. doi: 10.5482/HAMO-13-09-0047. Epub 2013 Nov 29. Review.

PMID:
24287886
4.

An algorithm for managing warfarin resistance.

Osinbowale O, Al Malki M, Schade A, Bartholomew JR.

Cleve Clin J Med. 2009 Dec;76(12):724-30. doi: 10.3949/ccjm.76a.09062. Review.

5.

Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.

Natarajan S, Ponde CK, Rajani RM, Jijina F, Gursahani R, Dhairyawan PP, Ashavaid TF.

Pharmacol Rep. 2013;65(5):1375-82.

6.

Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients.

Tomita H, Kadokami T, Momii H, Kawamura N, Yoshida M, Inou T, Fukuizumi Y, Usui M, Funakoshi K, Yamada S, Aomori T, Yamamoto K, Uno T, Ando S; ATTACK-WF research group.

Thromb Res. 2013 Nov;132(5):537-42. doi: 10.1016/j.thromres.2013.09.003. Epub 2013 Sep 10.

PMID:
24071466
7.

Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin.

Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA.

J Thromb Thrombolysis. 2007 Oct;24(2):93-7. Epub 2007 Mar 23.

PMID:
17380255
8.

A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.

Fregin A, Czogalla KJ, Gansler J, Rost S, Taverna M, Watzka M, Bevans CG, Müller CR, Oldenburg J.

J Thromb Haemost. 2013 May;11(5):872-80. doi: 10.1111/jth.12185.

9.

Supratherapeutic international normalized ratio due to reduced vitamin K intake secondary to prolonged vomiting in a patient on warfarin.

Reaves AB, Clarke CJ, Tillman EM.

Ann Pharmacother. 2013 Jun;47(6):e28. doi: 10.1345/aph.1R688.

PMID:
23719786
10.

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF.

J Thromb Haemost. 2010 Jan;8(1):95-100. doi: 10.1111/j.1538-7836.2009.03677.x. Epub 2009 Oct 30.

11.

Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.

Müller E, Keller A, Fregin A, Müller CR, Rost S.

BMC Genet. 2014 Feb 4;15:17. doi: 10.1186/1471-2156-15-17.

12.

A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.

Ainle FN, Mumford A, Tallon E, McCarthy D, Murphy K.

Ir J Med Sci. 2008 Jun;177(2):159-61. doi: 10.1007/s11845-008-0126-2. Epub 2008 Feb 12.

PMID:
18266023
13.

Low-dose vitamin K to augment anticoagulation control.

Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI.

Pharmacotherapy. 2005 Dec;25(12):1746-51.

PMID:
16305294
14.

Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.

Kim HO, Lee KE, Park HY, Lee NR, Oh BR, Chang BC, Gwak HS.

J Pharm Pharmacol. 2013 Aug;65(8):1195-203. doi: 10.1111/jphp.12084. Epub 2013 May 28.

PMID:
23837587
15.

Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases.

Denas G, Marzot F, Offelli P, Stendardo A, Cucchini U, Russo R, Nante G, Iliceto S, Pengo V.

J Thromb Thrombolysis. 2009 Apr;27(3):340-7. doi: 10.1007/s11239-008-0211-4. Epub 2008 Mar 13.

PMID:
18338109
16.

Prediction of optimal warfarin maintenance dose using advanced artificial neural networks.

Grossi E, Podda GM, Pugliano M, Gabba S, Verri A, Carpani G, Buscema M, Casazza G, Cattaneo M.

Pharmacogenomics. 2014 Jan;15(1):29-37. doi: 10.2217/pgs.13.212.

PMID:
24329188
17.

Genetic determinants of response to warfarin during initial anticoagulation.

Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM.

N Engl J Med. 2008 Mar 6;358(10):999-1008. doi: 10.1056/NEJMoa0708078.

18.

Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

Tomisti L, Del Re M, Bartalena L, Tanda ML, Pucci A, Pambianco F, Danesi R, Braverman LE, Martino E, Bogazzi F.

Endocr Pract. 2013 Nov-Dec;19(6):1043-9. doi: 10.4158/EP13093.RA. Review.

PMID:
23807523
19.

Genotype-guided dosing of warfarin.

Mega JL, Giugliano RP.

Clin Chem. 2014 Jul;60(7):920-2. doi: 10.1373/clinchem.2013.220004. Epub 2014 Apr 1. No abstract available.

20.

Warfarin resistance.

Sinxadi P, Blockman M.

Cardiovasc J Afr. 2008 Jul-Aug;19(4):215-7. Review.

Items per page

Supplemental Content

Write to the Help Desk